MediciNova Completes Phase 2 Trial for MN-001 in NAFLD and Type 2 Diabetes Patients

MediciNova Reaches Important Clinical Milestone

MediciNova has announced the completion of the last patient last visit (LPLV) in its phase 2 clinical study called MN-001-NATG-202.

The study is evaluating MN-001, also known as tipelukast, for patients suffering from hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM).

This marks an important step for the company because it means all patient visits in the study are now complete, and the company can move toward analyzing the clinical data.

Top-line study results are expected during the third quarter of 2026.

What the Phase 2 Study Was Testing

The MN-001-NATG-202 study was designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial.

Patients participating in the study were randomly divided into two groups:

• One group received 500 mg per day of MN-001 

• The second group received placebo treatment 

The treatment period lasted for 24 weeks.

The study mainly focused on two co-primary endpoints:

• Change in liver fat content measured using controlled attenuation parameter (CAP) score 

• Change in fasting serum triglyceride levels at Week 24 

Researchers are also evaluating several secondary endpoints, including:

• Safety of the treatment 

• Drug tolerability 

• Changes in cholesterol levels such as HDL-C, LDL-C, and total cholesterol 

Why This Study Matters

Patients with type 2 diabetes often face multiple metabolic problems at the same time.

Many people with T2DM also develop:

• High triglyceride levels 

• High cholesterol 

• Fat accumulation in the liver 

These conditions can increase the risk of cardiovascular disease and liver damage over time.

NAFLD has become one of the most common liver diseases globally, especially among patients with obesity and diabetes. Because there are still limited treatment options available, companies are actively working on new therapies that can target both metabolic disorders and liver disease together.

MediciNova believes MN-001 could potentially help address these problems through multiple biological mechanisms.

How MN-001 Works

MN-001, or tipelukast, is an oral small-molecule drug candidate.

The company says the drug may provide anti-inflammatory and antifibrotic effects through several mechanisms.

These include:

• Leukotriene receptor antagonism 

• Inhibition of phosphodiesterase enzymes, mainly PDE-3 and PDE-4 

• Inhibition of 5-lipoxygenase (5-LO) 

Researchers believe the 5-LO and leukotriene pathway may play an important role in fibrosis development.

According to MediciNova, MN-001 has shown the ability in preclinical studies to reduce the activity of genes linked to fibrosis, including:

• LOXL2 

• Collagen Type 1 

• TIMP-1 

The drug has also shown effects on inflammatory genes such as CCR2 and MCP-1.

In addition, the company says MN-001 may help reduce triglyceride production in liver cells by blocking arachidonic acid uptake.

Additional Research Around MN-001

Recent research has also highlighted the activity of MN-002, the major metabolite of MN-001.

According to the company, MN-002 may help improve cholesterol efflux in macrophages by increasing important transport proteins called ABCA1 and ABCG1.

This could potentially support better lipid metabolism and cardiovascular health.

Understanding T2DM, Dyslipidemia, and NAFLD

Type 2 diabetes mellitus is mainly driven by insulin resistance.

When insulin resistance develops, the body starts having trouble controlling blood sugar and lipid metabolism properly. This often leads to dyslipidemia, which means abnormal lipid levels in the blood.

Hypertriglyceridemia is very common in patients with T2DM because the liver produces more fat while the body clears triglycerides less efficiently.

At the same time, many patients also experience:

• Increased LDL cholesterol 

• Lower HDL cholesterol 

These metabolic changes raise the risk of heart disease and liver complications.

NAFLD is considered one of the major liver-related complications associated with insulin resistance and diabetes.

About MediciNova

MediciNova is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases.

The company’s pipeline is mainly built around two compounds:

• MN-166 (ibudilast) 

• MN-001 (tipelukast) 

MediciNova currently has 11 clinical development programs underway.

Its lead candidate, MN-166, is in phase 3 development for:

• Amyotrophic lateral sclerosis (ALS) 

• Degenerative cervical myelopathy (DCM) 

The drug is also considered phase 3-ready for progressive multiple sclerosis and is being evaluated in phase 2 studies for Long COVID and substance dependence.

Meanwhile, MN-001 has already been studied in phase 2 trials for idiopathic pulmonary fibrosis (IPF), while the NAFLD programme continues moving forward.

Conclusion

The completion of the MN-001-NATG-202 phase 2 study is an important development for MediciNova’s metabolic disease pipeline.

As rates of type 2 diabetes, dyslipidemia, and fatty liver disease continue rising worldwide, there is growing demand for therapies that can address multiple metabolic complications together.

With top-line data expected in 2026, investors and healthcare researchers will be closely watching whether MN-001 can demonstrate meaningful benefits for patients with NAFLD and diabetes-related lipid disorders.